Kyntra Bio, Inc. KYNB
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -37.14% | 6.35% | -78.26% | -72.44% | -89.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -37.14% | 6.35% | -78.26% | -72.44% | -89.53% |
| Cost of Revenue | -52.63% | -68.65% | -81.81% | -75.87% | -72.09% |
| Gross Profit | 54.90% | 75.47% | 82.84% | 76.66% | 63.08% |
| SG&A Expenses | -15.81% | -37.47% | -43.83% | -49.78% | -55.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.22% | -58.46% | -71.50% | -68.99% | -67.67% |
| Operating Income | 39.40% | 62.32% | 70.18% | 68.43% | 60.35% |
| Income Before Tax | 64.66% | 53.21% | 61.99% | 74.74% | 60.67% |
| Income Tax Expenses | 98.82% | 66.42% | 66.54% | 66.28% | 52.78% |
| Earnings from Continuing Operations | 64.63% | 53.18% | 61.98% | 74.75% | 60.68% |
| Earnings from Discontinued Operations | 150.89% | 98.70% | 129.02% | 214.55% | 58.14% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8,966.99% | 1,735.01% | 485.57% | 277.07% | 98.77% |
| EBIT | 39.40% | 62.32% | 70.18% | 68.43% | 60.35% |
| EBITDA | 38.44% | 61.97% | 70.15% | 74.08% | 66.70% |
| EPS Basic | 8,771.76% | 1,696.65% | 478.03% | 273.56% | 98.78% |
| Normalized Basic EPS | 37.94% | 59.82% | 67.38% | 48.81% | 40.92% |
| EPS Diluted | 8,771.76% | 1,696.65% | 478.03% | 273.56% | 98.78% |
| Normalized Diluted EPS | 37.94% | 59.82% | 67.38% | 48.81% | 40.92% |
| Average Basic Shares Outstanding | 0.31% | 0.58% | 1.02% | 1.53% | 1.97% |
| Average Diluted Shares Outstanding | 0.31% | 0.58% | 1.02% | 1.53% | 1.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |